Add BrightSurf on Google Email

Vaccine uptake remains low among at-risk Canadians

Researchers from McGill University found that pneumococcal vaccination uptake is low among adults at high risk in Canada. Despite the importance of pneumococcal vaccination to prevent pneumonia and other forms of pneumococcal disease, many people missed opportunities for vaccination.

SourceMcGill University·JournalPLOS ONE·TypeData/statistical analysis·DateNov 2, 2022

Controlling gut flora can reduce mortality in critically ill patients on life support

A randomized clinical trial found that applying topical antibiotics to the upper digestive tract can improve survival rates in mechanically ventilated intensive care patients. The study, published in JAMA, also showed a significant reduction in new hospital-acquired infections.

SourceGeorge Institute for Global Health·JournalJournal of the American Medical Association·TypeRandomized controlled/clinical trial·DateOct 26, 2022

How bacteria defuse hypothiocyanite, an antimicrobial weapon of the innate immune system

Researchers discovered a novel role for an E. coli enzyme in reducing the toxic effects of hypothiocyanite, a key antimicrobial released by the human immune system. This finding has implications for diseases like cystic fibrosis and inflammatory bowel disease, as it suggests that various bacteria can evade this powerful oxidant.

SourceUniversity of Alabama at Birmingham·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateAug 10, 2022

Nanoparticle sensor can distinguish between viral and bacterial pneumonia

Researchers developed a nanoparticle sensor that can accurately distinguish between viral and bacterial pneumonia within two hours using a simple urine test. The sensor uses the host's immune response to infection, detecting specific protease patterns that serve as signatures of bacterial or viral infection.

SourceMassachusetts Institute of Technology·JournalProceedings of the National Academy of Sciences·DateJun 13, 2022

New type of pneumococcal vaccine developed by KI scientists

Researchers at Karolinska Institutet have identified a new vaccine candidate based on nano-sized membrane vesicles that provide protection against multiple pneumococcal strains. The vaccine target two conserved lipoproteins MalX and PrsA, showing serotype-independent cross-protection.

SourceKarolinska Institutet·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJun 2, 2022

COVID-19 vaccine impact on chest CT of pneumonia in symptomatic patients

A single-center study found lower pneumonia frequency and severity in fully vaccinated patients compared to unvaccinated patients. The study included 467 patients who underwent chest CT during hospitalization for symptomatic COVID-19, with significant reductions in pneumonia frequency and severity observed in those fully vaccinated.

SourceAmerican Roentgen Ray Society·JournalAmerican Journal of Roentgenology·TypeImaging analysis·DateMay 31, 2022

New guidance released for preventing hospital-acquired pneumonia

The Society for Healthcare Epidemiology of America and four medical societies release recommendations for preventing ventilator-associated events and nonventilator hospital-acquired pneumonia. Evidence-based practices include oral care, managing dysphagia, and multimodal approaches to prevent viral infections.

SourceSociety for Healthcare Epidemiology of America·JournalInfection Control and Hospital Epidemiology·TypeLiterature review·DateMay 20, 2022

COVID-19 pneumonia increases dementia risk

Patients hospitalized with COVID-19 pneumonia are at a higher risk of developing new-onset dementia compared to those with other types of pneumonia, according to a recent study. The median time interval between infection and dementia diagnosis was 182 days for COVID-19 patients.

SourceUniversity of Missouri-Columbia·JournalOpen Forum Infectious Diseases·TypeData/statistical analysis·DateApr 19, 2022

Discovery could pave way for new lung treatment

Researchers have identified a new family of proteins in blood vessels that prevent fluid from entering the lungs, offering a potential new avenue for treating acute respiratory distress syndrome. Stimulating these bitter taste receptors has been shown to provide protection against fluid leak into the lung.

SourceAnglia Ruskin University·JournalFrontiers in Physiology·DateMar 23, 2022

Electronic pneumonia decision support helps reduce mortality by 38% in community hospitals

A real-time electronic decision support system helped reduce intensive care unit admissions, improve antibiotic use, and lower overall mortality rates for patients with pneumonia. The study found a 38% decrease in mortality among community hospital patients using the system.

SourceIntermountain Healthcare·JournalAmerican Journal of Respiratory and Critical Care Medicine·TypeRandomized controlled/clinical trial·DateMar 9, 2022

SMART researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria

SMART researchers identified a novel phage lysin, Abp013, with promising antimicrobial ability against Acinetobacter baumannii and Klebsiella pneumoniae. The study demonstrated Abp013's ability to effectively target complex bacterial environments and could advance treatment methods for multidrug-resistant Gram-negative pathogens.

SourceSingapore-MIT Alliance for Research and Technology (SMART)·JournalAntibiotics·TypeExperimental study·DateFeb 17, 2022

Pulse oximeter measurements of blood oxygen levels are unreliable in assessing severity of Covid-19 pneumonia across different ethnic groups

A study published in European Respiratory Journal found pulse oximeters give false readings of up to 7% higher in patients with Mixed, Black, and Asian ethnicities compared to White patients. This can delay timely treatment for Covid-19 pneumonia, leading to poorer outcomes.

SourceUniversity of Nottingham·JournalEuropean Respiratory Journal·TypeExperimental study·DateJan 27, 2022

Hospitals have ethical obligation to care for unvaccinated severe COVID-19 patients

A new opinion piece argues that hospitals have an ethical duty to care for unvaccinated severe COVID-19 patients, even if it means delaying non-emergency procedures for vaccinated individuals. The author suggests a contingency care standard prioritizing emergency life-support regardless of vaccination status.

SourceAmerican Thoracic Society·JournalAnnals of the American Thoracic Society·TypeCommentary/editorial·DateDec 3, 2021

$4.6 million NIH grant to study mechanical ventilator protocols for COVID and other critically-ill ICU patients

The $4.6 million NIH grant will help implement a telehealth-enabled audit and feedback process to monitor adherence to recognized standards of care in 14 Intermountain Healthcare ICUs. This study aims to reduce the time patients spend on mechanical ventilators, improving lung protective mechanical ventilation best practices.

SourceIntermountain Healthcare·TypeRandomized controlled/clinical trial·DateDec 1, 2021

New group of antibacterial molecules identified

Researchers at Karolinska Institutet have discovered a new group of small antibacterial compounds that inhibit the formation of bacterial cell walls, showing promise against antibiotic-resistant strains. The molecules work by binding to lipid II, a crucial molecule for bacterial cell wall construction.

SourceKarolinska Institutet·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 17, 2021

New study shows environmental and social factors contribute to higher rates of pneumonia in children

A new study found that exposure to particulate matter pollution and social factors such as race and socioeconomic status contribute to higher rates of community acquired pneumonia in children. Researchers used satellite data to identify high- and low-risk areas for the disease, highlighting the need for policy adjustments.

SourceLouisiana State University·JournalExperimental Biology and Medicine·TypeData/statistical analysis·DateOct 29, 2021

Tailoring treatment of patients with the lung disease COPD

The study found that patients with low risk of exacerbations do not benefit from low to moderate dose inhaled corticosteroids, while high doses are associated with severe side effects. Tailoring treatment according to patient characteristics, such as age and blood cell count, can minimize over- and underuse of inhaled corticosteroids.

SourceUniversity of Zurich·JournalThe Lancet Digital Health·TypeNews article·DateAug 25, 2021

Understanding lung damage in patients with COVID-19

Researchers used a hamster model to study COVID-19 lung damage, discovering that the immune system's response plays a crucial role in disease progression. They found that certain cells involved in lung immunity ingest the virus, triggering an inflammatory response that can be brought under control by T cells.

SourceMax Delbrück Center for Molecular Medicine in the Helmholtz Association·JournalNature Communications·TypeNews article·DateAug 11, 2021